Because both peptides promote angiogenesis (new blood vessel growth), they are strictly contraindicated for anyone with an active malignancy or a history of cancer
The findings, which were presented over the weekend at ENDO 2026, the Endocrine Society's annual meeting, were based on an analysis of health records from more than 42,000 adults who were already taking at least two types of blood pressure medications when they began treatment with GLP-1 drugs such as semaglutide, tirzepatide or liraglutide
Actual medication appearance may differ from website imagery
In addition, people with coronary artery disease who use L-carnitine along with standard medications may be able to sustain physical activity for longer periods of time
References Bodnaruc, A.M., Prudhomme, D., Blanchet, R
Hampel, H